Benjamin Besse, MD, PhD, on NSCLC: Neoadjuvant Atezolizumab for Resectable Disease

September 22, 2020 By The ASCO Post Staff

Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses results of the phase II PRINCEPS trial, which assessed, for the first time, the effect of just one injection of the immunotherapy atezolizumab before surgery in patients with resectable non–small cell lung cancer (Abstract 1215O).

Related Content